ATB Therapeutics secured €54 million in Series A funding, one of Belgium's largest early-stage biotech raises. Backed by major global investors like EQT Life Sciences and...
Laminar Pharma raised €5.9 million, led by the Matutes family, for its growth and launch of anti-tumor drug LAM 561, aimed at glioblastoma treatment. Additional investors...
The company, founded in 2015, although the project started in 2017, raised $601,000 (€600,000)in January 2021 to start the process of clinical validation of its device....